Human Immunodeficiency Virus (HIV) Tests – In Vitro Diagnostic Market Analysis and Forecast Model
- Pages: 0
- Published: April 2019
- Report Code: GDME327MM
Human Immunodeficiency Virus (HIV) has become one of the world’s most serious health issues affecting approximately 36.9 million people. The epidemiology of HIV infections varies from one geographical region to another. Sources indicate that in many countries, incidence rates for HIV have stabilized due to the campaigns that provide condoms, pre-exposure prophylaxis, sterile needles, syringes, antiretroviral therapy (ART), and prevention of mother-to-child transmission interventions. Conversely, increases are generally expected to occur in the number of surviving HIV patients and thus the number of HIV prevalent cases. Disease incidence and prevalence are not the only factors influencing the HIV Tests market. Sales of these devices are also heavily impacted by fluctuations in the number of pregnant women, semen donations, whole blood donations, and source plasma donations.
The predominant devices used for HIV detection are enzyme immunoassay (EIA) tests, owing to their high specificity and sensitivity as well as their ability to be adapted for high-throughput testing. EIA HIV devices are used for disease diagnosis as well as screening of whole blood, source plasma, and sperm donations as well as for pregnant women screening. Point-of-care (POC) devices are also sometimes used for HIV screening due to their easy use and lack of complex, laboratory infrastructure. Nucleic acid amplification (NAAT) are sometimes used as confirmatory tests for samples that have already tested positive for HIV through EIA. Additionally, NAAT may be used as an additional screening test for whole blood or source plasma donations, for samples that return an indeterminate result on the HIV-1/HIV-2 antibody differentiation immunoassay, or for patients suspected of having an early infection, for example due to recent HIV exposure.
Who should buy this report?
This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for:
• CMO executives who must have deep understanding of the Human Immunodeficiency Virus (HIV) Tests- marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.
Currently marketed Human Immunodeficiency Virus (HIV) Tests – and evolving competitive landscape:
• Insightful review of the key industry trends.
• Annualized total Human Immunodeficiency Virus (HIV) Tests – market revenue by segment and market outlooks from 2015–2028.
• Granular data on total procedures, units, average selling prices and market values by segment.
Reasons to buy
The model will enable you to:
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Human Immunodeficiency Virus (HIV) Tests- market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Human Immunodeficiency Virus (HIV) Tests- market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Human Immunodeficiency Virus (HIV) Tests- market from 2015-2028.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• Abbott Laboratories
• Becton Dickinson and Co
• Danaher Corporation (Beckman Coulter Inc)
• Bio-Rad Laboratories Inc
• Hologic Inc
• OraSure Technologies Inc
• Ortho-Clinical Diagnostics Inc
• Bio Manguinhos and Fiocruz
• Grifols, S.A
• F. Hoffmann-La Roche Ltd
• Siemens Healthineers AG
• Qiagen NV
• Danaher Corporation (Cepheid)
• Trinity Biotech Plc